Canarypox and fowlpox viruses as recombinant vaccine vectors: an ultrastructural comparative analysis

  title={Canarypox and fowlpox viruses as recombinant vaccine vectors: an ultrastructural comparative analysis},
  author={Sole Maria Pacchioni and Luca Volont{\'e} and Carlo Zanotto and Eleana Pozzi and Carlo Giuli Morghen and Antonia Radaelli},
  journal={Archives of Virology},
Due to their natural host-range restriction to avian species, canarypox virus (CP) and fowlpox virus (FP) represent efficient and safe vaccine vectors, as they correctly express transgenes in human cells, elicit complete immune responses, and show protective efficacy in preclinical animal models. At present, no information is available on the differences in the abortive replication of these two avipox viruses in mammalian cells. In the present study, the replicative cycles of CP and FP, wild… Expand
Canarypox and fowlpox viruses as recombinant vaccine vectors: a biological and immunological comparison.
This study demonstrates that the heterologous HIV gag/pol and env genes are more efficiently expressed by fowlpox in non-immune and immune cells. Expand
Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes
Construction of novel FPgp and FPenv recombinants that express the highly immunogenic SIV Gag-pro and Env structural antigens are reported on, which may enhance the immunogenicity of Env peptides presented by MHC-II and provide CD4+ T-cell stimulation. Expand
The L1 protein of human papilloma virus 16 expressed by a fowlpox virus recombinant can assemble into virus-like particles in mammalian cell lines but elicits a non-neutralising humoral response.
It is demonstrated that the FPL1 recombinant better expresses L1 in the absence of GFP, correctly assembles structured capsomers into VLPs, and elicits an immune response in a preclinical animal model, the first report of HPV VLP assembled in eukaryotic cells using an avipox recombinant. Expand
L1R, A27L, A33R and B5R vaccinia virus genes expressed by fowlpox recombinants as putative novel orthopoxvirus vaccines
Four novel viral recombinants constructed based on the fowlpox genetic background might represent safer and more promising immunogens that can circumvent neutralisation by vector-generated immunity in smallpox-vaccine-experienced humans. Expand
Six host-range restricted poxviruses from three genera induce distinct gene expression profiles in an in vivo mouse model
Six, genetically diverse host-restricted poxviruses produce different responses in a mouse model early after infection, which may affect the immune response induced to vaccine antigen in vectors based on these viruses. Expand
Construction of a recombinant avipoxvirus expressing the env gene of Zika virus as a novel putative preventive vaccine
Although BALB/c mice appear to be an adequate model for ZIKV infection, as it mimics the natural mild infection in human beings, inadequate immune suppression seemed to occur by dexamethasone and different immune suppression strategies should be applied before challenge to reveal any protection of the mice. Expand
A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers
A preliminary indication for the prevention and treatment of HPV-related tumors by the use of DNA and avipox constructs as safe and effective immunogens following a prime/boost strategy is established. Expand
Vector Order Determines Protection against Pathogenic Simian Immunodeficiency Virus Infection in a Triple-Component Vaccine by Balancing CD4+ and CD8+ T-Cell Responses
Mucosal immunization with FWPV-based vaccines should be considered a potent prime in prime-boost vaccination protocols because it significantly protected animals against a repeated low-dose intrarectal challenge with pathogenic SIVmac251, resulting in a vaccine efficacy of 68%. Expand
Prime-boost therapeutic vaccination in mice with DNA/DNA or DNA/Fowlpox virus recombinants expressing the Human Papilloma Virus type 16 E6 and E7 mutated proteins fused to the coat protein of Potato virus X.
The therapeutic antitumor potency of a prime-boost vaccination strategy was explored, based on the mutated, nontransforming forms of the E6 and E7 oncogenes of Human Papilloma Virus type 16, fused to the Potato virus X (PVX) coat protein (CP) sequence, which improves the immunogenicity of tumor-associated antigens and may thus increase their efficacy. Expand
Virus–Plant Interactions: RNA Silencing
This chapter describes the defense system of plants and how viruses overcome it. Expand


Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells.
Early and late gene expression as well as genomic DNA replication was observed and viral morphogenesis was observed in monkey cells, with the production mainly of immature particles though smaller numbers of apparently mature virus particles were observed. Expand
Expression of HIV-1 envelope gene by recombinant avipox viruses.
Recombinant canarypox and fowlpox viruses that contained two forms of the HIV-1 (SF2 strain) env gene were engineered and their expression analysed in chick, simian and human cells, revealing the presence of specific antibodies in animals inoculated either with CP or with FP recombinants. Expand
Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry
Technical approaches to, and issues surrounding, the use of fowlpox virus as a recombinant vaccine vector in poultry and mammals are reviewed. Expand
Potential use of non-replicating vectors as recombinant vaccines.
Recombinant fowlpox and canarypox viruses which express immunogens from mammalian pathogens have been demonstrated to provide protective immunity on inoculation in non-avian species, which is a surprising result. Expand
Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system.
ALVAC-RG, a canarypox recombinant expressing the rabies glycoprotein gene, was inoculated intramuscularly into adult volunteers and could be used successfully for booster dosing at a 6 month interval, and induced functional antibody to rabies Glycoprotein and elicited cellular responses to rabie virus. Expand
Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine.
It is demonstrated that MVA can replicate, albeit poorly, in transformed human cell lines, but not in primary human fibroblasts although there is limited cell-to-cell spread and MVA is a potent inducer of type I interferon (IFN) from primary human cells, which may restrict virus spread in vivo. Expand
Recombinant fowlpox virus inducing protective immunity in non-avian species.
The results demonstrate the utility of a fowlpox virus vector in immunizing non-avian species against rabies in the absence of productive viral replication of thefowlpox vector. Expand
Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors
It is hoped that this body of data will contribute to a better understanding of the relevance of specific immunogenicity end points to protection and the predictive value of available animal models in HIV vaccine development. Expand
Humoral and cell-mediated immunity in rabbits immunized with live non-replicating avipox recombinants expressing the HIV-1SF2 env gene.
The results suggest that these recombinants might represent promising and safer candidate vaccines against HIV- 1 and indicate that rabbit sera possess group-specific antibodies, which were, however, unable to cross-neutralize divergent HIV-1 strains. Expand
Humoral and cell-mediated immunity in rabbits immunized with live non-replicating avipox recombinants expressing the HIV-1SF2env gene
The results suggest that canarypox and fowlpox recombinants might represent promising and safer candidate vaccines against HIV-1. Expand